Trump Says Anthropic No Longer Seen as National Security Threat 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
REDWOOD CITY, Calif., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th Annual Healthcare Conference on December 8, 2015 at 2:10 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Alex Dobbin
Associate Director, Investor Relations
650-421-9687
[email protected]
